A large-scale French study finds that patients hospitalized with COVID-19 face a significantly higher risk of long-term organ ...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the S&P ...